Baxter Heparin Recall Has Little Impact On Domestic Industry
This article was originally published in PharmAsia News
Baxter's recall of its heparin products has not brought negative impact on China's active pharmaceutical ingredient manufacturers. For instance, Shenzhen Hepalink Pharmaceutical, China's leading heparin API exporter, is exploring the expansion of its production. According to statistics from China Chamber of Commerce of Medicines & Health Products Importers & Exporters, heparin and its salt export reached $137 million in 2007, a 32.29 percent jump from the year before. Main export destinations include the U.S., Germany, Italy and France. Industry observers point out that China's heparin extract technology has long achieved standardization, but low-molecular-weight heparin did not enter the international market earlier due to quality issues and restrictions such as patent protection and drug approval. (Click here for more - Chinese Language)
You may also be interested in...
The merger between virtual care companies Teladoc and Livongo will offer individuals a wide range of tech-enabled care during a time when telehealth continues to grow.
Regeneron's antibody cocktail for SARS-Cov-2 is largely in holding mode for now, but the company announced progress on other fronts including for Dupixent in COPD and the NGF inhibitor fasinumab.
Market Intel: Why Telehealth, Digital Therapies Will Provide Mental Health Support Beyond COVID-19 Crisis
In this second part of a two-part series focusing on mental health tech, Medtech Insight highlights behavioral digital health companies that have attracted investors’ attention. Part one focused on transcranial magnetic stimulation.